Advances treatment of osteoporosis: New molecules, new strategies;Avancées thérapeutiques: Nouvelles molécules, nouvelles stratégies

Bulletin de l'Academie Nationale de Medecine

Volumn 194, Issue 8, 2010, Pages 1505-1518

  Orcel, Philippe ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Biological Therapy; Osteoporosis

Indexed keywords

EID: 79958844154     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)32180-6     Document Type: Article

References (31)

1. Roux S. -New treatment targets in osteoporosis. Joint Bone Spine, 2010, 77, 222-228.
2. VERNEJOUL M.G de, ORCEL P. -Nouvelles cibles thérapeutiques dans le traitement de l'ostéoporose. In : KAHN M.F., BARDIN T., MEYER O. et al. L'Actualité rhumatologique 2009 (Elsevier Masson, Edit), 2009, p. 245-254.
3. GRIFFITH J.F., ENGELKE K., GENANT H.K. -Looking beyond bone mineral density: Imaging assessment of bone quality. Ann. N. Y Acad. Sci., 2010, 1192, 45-56.
4. FUNCK-BRENTANO T., ORCEL P. -Osteoporose EMC-AKOS (Traité de Médecine) [7-0630] Doi: 10.1016/S1634-6939, 10, 39647-5.
5. http://afssaps.sante.fr/htm/5/rbp/ostemrec.htm
6. SHANE E., BURR D., EBELING P.R. -Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American society for bone and mineral Research. J. Bone Miner. Res., 2010, 25, 2267-2294.
7. CHMP assessment report on bisphosphonates and osteonecrosis of the jaw. http://www.ema. europa.eu/docs/en-GB/document-library/Report/2010/01/ WC500051428.pdf
8. KHOSLA S., BURR D., CAULEY J. et al. -American Society for Bone and Mineral Research. -Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res., 2007, 22, 1479-1491.
9. KEARNS A.E., KHOSLA S., KOSTENUIK P.J. -Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev., 2008, 29, 155-192.
10. MCCLUNG M.R., LEWIECKI E.M., COHEN S.B. et al. -AMG 162 Bone Loss Study Group. -Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med., 2006, 354, 821-831.
11. BROWN J.P., PRINCE R.L., DEAL G et al. -Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res., 2009, 14, 1-34.
12. MILLER P.D., BOLOGNESE M.A., LEWIECKI E.M. et al. -AMG Bone Loss Study Group. -Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone, 2008, 43, 222-229.
13. CUMMINGS S.R., SAN MARTIN J., MCCLUNG M.R. et al. -FREEDOM Trial. -Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med., 2009, 361, 756-765.
14. KENDLER D.L., ROUX C., BENHAMOU C.L. et al -Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone Miner. Res., 2010, 25, 72-81.
15. PAGEAU S.C. - Denosumab. Mabs, 2009, 1, 210-215.
16. VERNEJOUL M.C. de -Sclerosing bone disorders. Best Pract. Res. Clin. Rheumatol., 2008, 22, 71-83.
17. BONE H.G., MCCLUNG M.R., ROUX G et al. - Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res., 2010, 25, 937-947.
18. KARSDAL M.A., MARTIN T.J., BOLLERSLEV J. et al. -Are nonresorbing osteoclasts sources of bone anabolic activity? J. Bone Miner. Res., 2007, 22, 487-494.
19. PENNYPACKER B., SHEA M., LIU Q. et al. -Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone, 2009, 44, 199-207.
20. TRIVEDI R., MITHAL A., CHATTOPADHYAY N. -Recent updates on the calcium-sensing receptor as a drug target. Curr. Med Chem., 2008, 15, 178-186.
21. GOWEN M., STROUP G.B., DODDS R.A. et al. -Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest., 2000, 105, 1595-1604.
22. WINKLER D.G., SUTHERLAND M.K., GEOGHEGAN J.G et al. -Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J., 2003, 22, 6267-6276.
23. VERNEJOUL M.C. de. -Sclerosing bone disorders. Best Pract. Res. Clin. Rheumatol., 2008, 22, 71-83.
24. LI X., ZHANG Y., KANG H. et al. -Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem., 2005, 280, 19883-19887.
25. OMINSKY M.S., VLASSEROS F., JOLETTE J. et al. -Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density and bone strength. J. Bone Miner. Res., 2010, 25, 948-959.
26. Li X., WARMINGTON K.S., NIU Q.T. et al. -Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass and bone strength in aged male rats. J. Bone Miner. Res., 2010, [Epub ahead of print].
27. PADHI D., JANG G., STOUCH B., et al. -Single dose, placebo -controlled, randomised study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res., 2011, 26, 19-26.
28. WAGNER E.R., ZHU G., ZHANG B.Q. et al. -The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders. Curr. Mol. Pharmacol., 2010, [Epub ahead of print].
29. CANALIS E. - Update in new anabolic therapies for osteoporosis. J. Clin. Endocrinol. Metab., 2010, 9, 1496-1504.
30. BRIOT K., TRÉMOLLIÈRES F., THOMAS T. et al. -How long should patients take medications for postmenopausal osteoporosis ? Joint Bone Spine, 2007, 74, 24-31.
31. ROUSIERE M., NAVEAU B., ORCEL PH. -Traitement de l'ostéoporose: quand arrêter les traitements ? In : KAHN M.F., BARDIN T., MEYER O. et al. L'Actualité rhumatologique 2010. (Elsevier Masson Edit), 351-369.